NCT04708249

D-chiroinositol Administration in Hypogonadal Males

D-chiroinositol Administration for Testosterone Level Improvement in Hypogonadal Males

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Lo.Li.Pharma s.r.l · Industry
• Sex: Male
• Age: 65 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

D-chiroinositol (DCI), is known as second messenger of insulin pathway, but recently several works have reported the influence of DCI on steroidogenesis. In particular, the DCI capabilities to regulate aromatase expression and testosterone biosynthesis are arising. In this regard, DCI administration in case of reduced levels of testosterone, could be a good therapeutic opportunity. For this reason, the treatment of Late-Onset Male Hypogonadism (LOH) in undoubtedly an interesting target. LOH is a reduction of testosterone level due to advancing age, currently treated with Testosterone Replacement Therapy (TRT). Unfortunately, there is a lack of information about TRT safety, especially in older men. For these reasons, the aim of this study is to evaluate the effect of DCI treatment on testosterone accumulation in LOH patient.

Conditions

• Male Hypogonadism
• Sexual Dysfunction

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	D-chiroinositol	Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.

Timeline

• Start date: 2021-01-18
• Primary completion: 2021-02-24
• Completion: 2021-03-01
• First posted: 2021-01-13
• Last updated: 2021-03-02

Locations

1 site across 1 country: Italy